Spot-light on microbiota in obesity and cancer.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
23
09
2020
accepted:
18
05
2021
revised:
26
03
2021
pubmed:
8
8
2021
medline:
2
2
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
Over the last few years, the complexity and diversity of gut microbiota within and across individuals has been detailed in relation to human health. Further, understanding of the bidirectional association between gut microbiota and metabolic disorders has highlighted a complimentary, yet crucial role for microbiota in the onset and progression of obesity-related cancers. While strategies for cancer prevention and cure are known to work efficiently when supported by healthy diet and lifestyle choices and physical activity, emerging evidence suggests that the complex interplay relating microbiota both to neoplastic and metabolic diseases could aid strategies for cancer treatment and outcomes. This review will explore the experimental and clinical grounds supporting the functional role of gut microbiota in the pathophysiology and progression of cancers in relation to obesity and its metabolic correlates. Therapeutic approaches aiding microbiota restoration in connection with cancer treatments will be discussed.
Identifiants
pubmed: 34363002
doi: 10.1038/s41366-021-00866-7
pii: 10.1038/s41366-021-00866-7
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2291-2299Investigateurs
Annamaria Colao
(A)
Silvia Savastano
(S)
Silvia Magno
(S)
Andrea Di Nisio
(A)
Fiammetta Romano
(F)
Giovanna Muscogiuri
(G)
Eleonora Poggiogalle
(E)
Mary Venneri
(M)
Alessia Liccardi
(A)
Maria Grazia Tarsitano
(MG)
Luigi Barrea
(L)
Laura Di Renzo
(L)
Dario Tuccinardi
(D)
Massimiliano Caprio
(M)
Maria Angela Guzzardi
(MA)
Caterina Pelosini
(C)
Gabriella Pugliese
(G)
Filomena Bottiglieri
(F)
Sara Aprano
(S)
Davide Menafra
(D)
Gianluca Gortan Capellari
(GG)
Daniela Laudisio
(D)
Francesca Pivari
(F)
Caterina Brasacchio
(C)
Andrea Lenzi
(A)
Fabrizio Muratori
(F)
Ferruccio Santini
(F)
Luca Busetto
(L)
Paolo Sbraccia
(P)
Laura Soldati
(L)
Domenico Salvatore
(D)
Carolina Di Somma
(C)
Dario Giugliano
(D)
Lucio Gnessi
(L)
Brunella Capaldo
(B)
Gabriele Riccardi
(G)
Rocco Barazzoni
(R)
Brunella Guida
(B)
Maurizio Bifulco
(M)
Katherine Esposito
(K)
Roberto Vettor
(R)
Paolo Emidio Macchia
(PE)
Felipe Casanueva
(F)
Carla Lubrano
(C)
Francesco Beguinot
(F)
Giovanni Spera
(G)
Annamaria Belfiore
(A)
Luigi Di Luigi
(L)
Alberto Ritieni
(A)
Raffaele Napoli
(R)
Olga Vaccaro
(O)
Samir Sukkar
(S)
Carlo Alviggi
(C)
Rosario Pivonello
(R)
Giuseppe Bellastella
(G)
Giovanni Scambia
(G)
Giuseppe Bifulco
(G)
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
World Health Organization (WHO). Fact-sheets on cardiovascular disease. 2017. Available at: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases- (cvds).
Arnold M, Leitzmann M, Freisling H, Bray F, Romieu I, Renehan A, et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 2016;41:8–15.
pubmed: 26775081
doi: 10.1016/j.canep.2016.01.003
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Canc Inst. 1981;66:1191–308.
doi: 10.1093/jnci/66.6.1192
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.
pubmed: 12711737
doi: 10.1056/NEJMoa021423
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer–Viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8.
pubmed: 27557308
pmcid: 6754861
doi: 10.1056/NEJMsr1606602
Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Investig. 2011;121:2094–101.
pubmed: 21633177
pmcid: 3104761
doi: 10.1172/JCI45887
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Investig. 2007;117:175–84.
pubmed: 17200717
pmcid: 1716210
doi: 10.1172/JCI29881
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46:2347–55.
pubmed: 16150820
doi: 10.1194/jlr.M500294-JLR200
Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683–9.
pubmed: 11278967
doi: 10.1074/jbc.M011695200
Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leuk Biol. 2000;68:437–46.
doi: 10.1189/jlb.68.4.437
Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014;1842:446–62.
pubmed: 23707515
doi: 10.1016/j.bbadis.2013.05.017
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–48.
pubmed: 26823198
doi: 10.1016/j.metabol.2015.12.012
Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015;6:e2037.
pubmed: 26720346
pmcid: 4720912
doi: 10.1038/cddis.2015.381
Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Ann Rev Nutr. 1991;11:393–412.
doi: 10.1146/annurev.nu.11.070191.002141
Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metabol. 1988;67:460–4.
doi: 10.1210/jcem-67-3-460
Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1:611–21.
pubmed: 26182172
pmcid: 5070941
doi: 10.1001/jamaoncol.2015.1546
Park J, Kusminski CM, Chua SC, Scherer PE. Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am J Pathol. 2010;177:3133–44.
pubmed: 21056997
pmcid: 2993284
doi: 10.2353/ajpath.2010.100595
Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. Cancer Res. 2015;75:2375–86.
pubmed: 25840984
pmcid: 4694051
doi: 10.1158/0008-5472.CAN-14-3076
Lipsey CC, Harbuzariu A, Daley-Brown D, Gonzalez-Perez RR. Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer. World J Methodol. 2016;6:43–55.
pubmed: 27019796
pmcid: 4804251
doi: 10.5662/wjm.v6.i1.43
Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem. 2006;17:145–56.
pubmed: 16426829
doi: 10.1016/j.jnutbio.2005.06.011
Mutoh M, Teraoka N, Takasu S, Takahashi M, Onuma K, Yamamoto M, et al. Loss of adiponectin promotes intestinal carcinogenesis in Min and wild-type mice. Gastroenterology. 2011;140:2000–8.
pubmed: 21334339
doi: 10.1053/j.gastro.2011.02.019
Liu Z, Brooks RS, Ciappio ED, Kim SJ, Crott JW, Bennett G, et al. Diet-induced obesity elevates colonic TNF-alpha in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesityassociated colorectal cancer. J Nutr Biochem. 2012;23:1207–13.
pubmed: 22209007
doi: 10.1016/j.jnutbio.2011.07.002
Matsui S, Okabayashi K, Tsuruta M, Shigeta K, Seishima R, Ishida T, et al. Interleukin-13 and its signaling pathway is associated with obesity-related colorectal tumorigenesis. Cancer Sci. 2019;110:2156–65.
pubmed: 31099450
pmcid: 6609806
doi: 10.1111/cas.14066
Sanford NN, Giovannucci EL, Ahn C, Dee EC, Mahal BA. Obesity and younger versus older onset colorectal cancer in the United States, 1998-2017. J Gastrointest Oncol. 2020;11:121–6.
pubmed: 32175114
pmcid: 7052754
doi: 10.21037/jgo.2019.12.07
European Association for the Study of the Liver (EASL); European Association for the Study of547 Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.
Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers. 2020;12:1290.
pmcid: 7281233
doi: 10.3390/cancers12051290
Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8.
pubmed: 17700568
pmcid: 2360408
doi: 10.1038/sj.bjc.6603932
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
pubmed: 18280327
doi: 10.1016/S0140-6736(08)60269-X
Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1399–412.
pubmed: 23707461
doi: 10.1016/j.cgh.2013.05.009
Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149:302–17.e1.
pubmed: 25957861
doi: 10.1053/j.gastro.2015.04.053
Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40:463–71.
pubmed: 23829164
doi: 10.3109/03014460.2013.807878
Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nature Rev Microbiol. 2017;15:630–8.
doi: 10.1038/nrmicro.2017.58
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–7.
pubmed: 22674330
doi: 10.1126/science.1223813
Everard A, Geurts L, Van Roye M, Delzenne NM, Cani PD. Tetrahydro Iso-alpha Acids from Hops Improve Glucose Homeostasis and Reduce Body Weight Gain and Metabolic Endotoxemia in High-fat Diet-fed Mice. PLoS ONE. 2012;7:e33858.
pubmed: 22470484
pmcid: 3314685
doi: 10.1371/journal.pone.0033858
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–83.
pubmed: 17823788
doi: 10.1007/s00125-007-0791-0
Marzullo P, Di Renzo L, Pugliese G, De Siena M, Barrea L, Muscogiuri G, et al. From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. Int J Obes Suppl. 2020;10:35–49.
pubmed: 32714511
pmcid: 7371682
doi: 10.1038/s41367-020-0017-1
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.
pubmed: 19043404
doi: 10.1038/nature07540
Mitsuoka T, Hayakawa K. Die Faecalflora bei Menschen. I. Die Zusammensetzung der Faecalflora der verschiedenen Altergruppen [The fecal flora in man. I. Composition of the fecal flora of various age groups]. Zentralbl Bakteriol Orig A. 1973;223:333–42.
pubmed: 4145840
Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol. 2006;72:1027–33.
pubmed: 16461645
pmcid: 1392899
doi: 10.1128/AEM.72.2.1027-1033.2006
Org E, Mehrabian M, Parks BW, Shipkova P, Liu X, Drake TA, Lusis AJ. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016;7:313–22.
pubmed: 27355107
pmcid: 4988450
doi: 10.1080/19490976.2016.1203502
Bolnick DI, Snowberg LK, Hirsch PE, Lauber CL, Org E, Parks B, et al. Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat Commun. 2014;5:4500.
pubmed: 25072318
doi: 10.1038/ncomms5500
Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, Goedert JJ. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99:4632–40.
pubmed: 25211668
pmcid: 4255131
doi: 10.1210/jc.2014-2222
Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12.
Gérard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73:147–62.
pubmed: 26459447
doi: 10.1007/s00018-015-2061-5
Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830.
pubmed: 30158926
pmcid: 6104162
doi: 10.3389/fimmu.2018.01830
Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 2018;25:79.
pubmed: 30413188
pmcid: 6234774
doi: 10.1186/s12929-018-0483-8
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
pubmed: 22575588
doi: 10.1016/S1470-2045(12)70137-7
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
Wroblewski LE, Peek RM Jr. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42:285–98.
pubmed: 23639641
pmcid: 3648881
doi: 10.1016/j.gtc.2013.01.006
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.
pubmed: 22009989
pmcid: 3266037
doi: 10.1101/gr.126516.111
Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes. 2014;5:675–80.
pubmed: 25483338
pmcid: 4615906
doi: 10.4161/19490976.2014.969989
Sears CL, Geis AL, Housseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Investig. 2014;124:4166–72.
pubmed: 25105360
pmcid: 4191034
doi: 10.1172/JCI72334
Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61:582–8.
pubmed: 21994333
doi: 10.1136/gutjnl-2011-300784
Zeng XT, Xia LY, Zhang YG, Li S, Leng WD, Kwong JS. Periodontal disease and incident lung cancer risk: a meta-analysis of cohort studies. J Periodontol. 2016;87:1158–64.
pubmed: 27294431
doi: 10.1902/jop.2016.150597
Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep. 2016;6:30751.
pubmed: 27485780
pmcid: 4971513
doi: 10.1038/srep30751
Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One. 2014;9:e83744.
pubmed: 24421902
pmcid: 3885448
doi: 10.1371/journal.pone.0083744
Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol. 2016;82:5039–48.
pubmed: 27342554
pmcid: 4968547
doi: 10.1128/AEM.01235-16
Wang H, Altemus J, Niazi F, Green H, Calhoun BC, Sturgis C, et al. Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget. 2017;8:88122–38.
pubmed: 29152146
pmcid: 5675698
doi: 10.18632/oncotarget.21490
Yang J, Tan Q, Fu Q, Zhou Y, Hu Y, Tang S, Zhou Y, et al. Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. Breast Cancer. 2017;24:220–8.
pubmed: 27709424
doi: 10.1007/s12282-016-0734-z
Shapira I, Sultan K, Lee A, Taioli E. Evolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancy. ISRN Oncol. 2013;2013:693920.
pubmed: 24187630
pmcid: 3800670
Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, et al. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Int J Cancer. 2012;130:1401–10.
pubmed: 21544804
doi: 10.1002/ijc.26157
Onoue M, Kado S, Sakaitani Y, Uchida K, Morotomi M. Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. Cancer Lett. 1997;113:179–186.
pubmed: 9065820
doi: 10.1016/S0304-3835(97)04698-3
Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–78.
pubmed: 26408641
doi: 10.1136/gutjnl-2015-309800
Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018;6:70.
pubmed: 29642940
pmcid: 5896039
doi: 10.1186/s40168-018-0451-2
Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16:690–704.
pubmed: 31554963
doi: 10.1038/s41575-019-0209-8
Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.
pubmed: 22516259
pmcid: 3332000
doi: 10.1016/j.ccr.2012.02.007
Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology. 2010;52:1322–33.
pubmed: 20803560
doi: 10.1002/hep.23845
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.
pubmed: 23803760
doi: 10.1038/nature12347
Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell. 2004;15:2156–63.
pubmed: 15004225
pmcid: 404012
doi: 10.1091/mbc.e03-12-0894
Gadaleta RM, Oldenburg B, Willemsen EC, Spit M, Murzilli S, Salvatore L, et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. Biochim Biophys Acta. 2011;1812:851–8.
pubmed: 21540105
doi: 10.1016/j.bbadis.2011.04.005
Sfanos KS, Canene-Adams K, Hempel H, Yu S-H, Simons B, Schaeffer A, et al. Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo[4,5-β]pyridine (PhIP)-induced cancer at multiple sites. Cancer Prev Res. 2015;8:683–92.
doi: 10.1158/1940-6207.CAPR-15-0090
Shoskes DA, Altemus J, Polackwich AS, Tucky B, Wang H, Eng C. The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. Urology. 2016;92:26–32.
pubmed: 26970449
doi: 10.1016/j.urology.2016.02.043
Shrestha E, White JR, Yu S-H, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199:161–71.
pubmed: 28797714
doi: 10.1016/j.juro.2017.08.001
Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018;15:11–24.
pubmed: 29089606
doi: 10.1038/nrurol.2017.167
Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108–19.
pubmed: 26754190
doi: 10.1038/nrurol.2015.301
Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther. 2008;7:1919–25.
pubmed: 18927500
doi: 10.4161/cbt.7.12.6940
Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831–5.
pubmed: 21051639
pmcid: 3110694
doi: 10.1126/science.1191175
Kang MJ, Kim HG, Kim JS, Oh DG, Um YJ, Seo CS, et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol. 2013;9:1295–308.
pubmed: 24033282
doi: 10.1517/17425255.2013.807798
Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70.
pubmed: 24264989
pmcid: 6709532
doi: 10.1126/science.1240527
Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016;45:931–43.
pubmed: 27717798
doi: 10.1016/j.immuni.2016.09.009
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6.
pubmed: 24264990
pmcid: 4048947
doi: 10.1126/science.1240537
Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 2010;467:967–71.
pubmed: 20962846
pmcid: 3108066
doi: 10.1038/nature09447
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016;165:276–87.
pubmed: 27058662
doi: 10.1016/j.cell.2016.03.001
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84.
pubmed: 26541610
pmcid: 4721659
doi: 10.1126/science.aad1329
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79.
pubmed: 28368458
doi: 10.1093/annonc/mdx108
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.
pubmed: 29097493
doi: 10.1126/science.aan4236
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9. https://doi.org/10.1126/science.aac4255 .
doi: 10.1126/science.aac4255
pubmed: 26541606
pmcid: 4873287
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
pubmed: 29097494
doi: 10.1126/science.aan3706
Luo J, Hendryx M, Manson JE, Figueiredo JC, LaBlanc ES, Barrington W, et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019;3:pkz054.
pubmed: 31737862
pmcid: 6795232
doi: 10.1093/jncics/pkz054
Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and metanalysis. Ann Oncol. 2014;25:1293–311.
pubmed: 24644304
doi: 10.1093/annonc/mdu012
Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev. 2011;12:282–294.
pubmed: 20880127
doi: 10.1111/j.1467-789X.2010.00805.x
Belligoli A, Bettini S, Busetto L. Bariatric surgery: Is a matter of cutting calories or cutting metabolic regulators? Curr Opin Endocr Metab Res. 2019;4:83–8.
doi: 10.1016/j.coemr.2018.08.001
Carlsson LM, Peltonen M, Ahlin S, Anveden A, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704.
pubmed: 22913680
doi: 10.1056/NEJMoa1112082
Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–62.
pubmed: 19556163
doi: 10.1016/S1470-2045(09)70159-7
Afshar S, Kelly SB, Seymour K, Lara J, Woodcock S, Mathers JC. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. Obes Surg. 2014;24:1793–9.
pubmed: 25015708
doi: 10.1007/s11695-014-1359-y
Derogar M, Hull MA, Kant P, Östlund M, Lu Y, Lagergren J. Increased risk of colorectal cancer after obesity surgery. Ann Surg. 2013;258:983–8.
pubmed: 23470581
doi: 10.1097/SLA.0b013e318288463a
Mackenzie H, Markar SR, Askari A, Faiz O, Hull M, Purkayastha S, et al. Obesity surgery and risk of cancer. Br J Surg. 2018;105:1650–7.
pubmed: 30003539
doi: 10.1002/bjs.10914
Feigelson HS, Caan B, Weinmann S, Leonard AC, Powers JD, Yenumula PR. et al. Bariatric surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. Ann Surg. 2020;272:1053–1059. https://doi.org/10.1097/SLA.0000000000003331 .
doi: 10.1097/SLA.0000000000003331
pubmed: 30998538
Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metabolism. 2015;22:228–38.
pubmed: 26244932
pmcid: 4537510
doi: 10.1016/j.cmet.2015.07.009
Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, et al. Roux-en-Y GAstric Bypass Surgery of Morbidly Obese Patients Induces Swift and Persistent Changes of the Individual Gut Microbiota. Genome Med. 2016;8:67.
pubmed: 27306058
pmcid: 4908688
doi: 10.1186/s13073-016-0312-1
Aron-Wisnewsky J, Prifti E, Belda E, Ichou F, Kayser BD, Dao MC, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 2019;68:70–82.
pubmed: 29899081
doi: 10.1136/gutjnl-2018-316103
Tarashi S, Siadat SD, Ahmadi Badi S, Zali M, Biassoni R, Ponzoni M, et al. Gut bacteria and their metabolites: which one is the defendant for colorectal cancer? Microorganisms. 2019;7:561.
pmcid: 6920974
doi: 10.3390/microorganisms7110561
Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis. 2015;26:25877.
pubmed: 25651995
Bodnaruc AM, Prud’homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab. 2016;13:92.
doi: 10.1186/s12986-016-0153-3
Taper HS, Roberfroid MB. Nontoxic potentiation of cancer chemotherapy by dietary oligofructose or inulin. Nutr Cancer. 2000;38:1–5.
pubmed: 11341034
doi: 10.1207/S15327914NC381_1
Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013;153:228–39. https://doi.org/10.1016/j.cell.2013.02.035
doi: 10.1016/j.cell.2013.02.035
pubmed: 23540700
pmcid: 3898468
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–14.
pubmed: 24912386
doi: 10.1038/nrgastro.2014.66
Gomes AC, de Sousa RG, Botelho PB, Gomes TL, Prada PO, Mota JF. The additional effects of a probiotic mix on abdominal adiposity and antioxidant status: a double-blind, randomized trial. Obesity. 2017;25:30–38.
pubmed: 28008750
doi: 10.1002/oby.21671
Cai S, Kandasamy M, Rahmat JN, Tham SM, Bay BH, Lee YK, et al. Lactobacillus rhamnosus GG ACtivation of Dendritic Cells and Neutrophils Depends on the Dose and Time of Exposure. J Immunol Res. 2016;2016:7402760.
pubmed: 27525288
pmcid: 4971325
doi: 10.1155/2016/7402760
Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7:12365.
pubmed: 27507542
pmcid: 4987524
doi: 10.1038/ncomms12365
Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA. 2016;113:E1306–15.
pubmed: 26884164
pmcid: 4780612
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–6.e7.
pubmed: 22728514
doi: 10.1053/j.gastro.2012.06.031
Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611–9.e6.
pubmed: 28978426
doi: 10.1016/j.cmet.2017.09.008
Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA. 2016;113:E1306–15.
pubmed: 26884164
pmcid: 4780612
Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145:2021–31.
pubmed: 30458058
doi: 10.1002/ijc.32003
Sinh P, Barrett TA, Yun L. Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract. 2011;2011:136064.
pubmed: 21915178
pmcid: 3171158
doi: 10.1155/2011/136064
Healy ME, Lahiri S, Hargett SR, Chow JD, Byrne FL, Breen DS, et al. Dietary sugar intake increases liver tumor incidence in female mice. Sci Rep. 2016;6:22292.
pubmed: 26924712
pmcid: 4770276
doi: 10.1038/srep22292
Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Investig. 2019;42:1365–86.
doi: 10.1007/s40618-019-01061-2
Chung HY, Park YK. Rationale, feasibility and acceptability of ketogenic diet for cancer treatment. J Cancer Prev. 2017;22:127–34.
pubmed: 29018777
pmcid: 5624453
doi: 10.15430/JCP.2017.22.3.127
Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochim Biophys Acta. 2011;1807:577–94.
pubmed: 20804725
doi: 10.1016/j.bbabio.2010.08.009